Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy.
E. S. Antonarakis
No relevant relationships to disclose
A. S. Kibel
Consultant or Advisory Role - Centocor Ortho Biotech; Dendreon; Sanofi
Honoraria - Centocor Ortho Biotech; Dendreon; Sanofi
D. W. Lin
Honoraria - Dendreon
R. C. Tyler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
M. Tabesh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
C. G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon
Honoraria - Institute for Medical Education Research
Other Remuneration - Bristol-Myers Squibb